The type III TGF-β receptor suppresses breast cancer progression
J. Clin. Invest. Mei Dong, et al. 117:206 doi:10.1172/JCI29293 [Go to this article.]

Figure 7
Restoration of TβRIII expression inhibits Matrigel invasiveness of MDA-MB231 breast cancer cells. (A) MDA-MB231 cells were infected with equivalent amounts of adenoviral constructs carrying GFP, HA-tagged TβRIII, and a TβRIII mutant lacking the entire cytoplasmic domain (TβRIIIΔcyto). Expression of the transgenes was confirmed by Western blotting of cell lysate using anti-HA antibody. (B and C) Matrigel invasion assay. Adenovirally infected MDA-MB231 cells (75,000 cells) were seeded in a Matrigel-coated upper chamber and treated with TGF-β1 (15 pM) 2 hours later. Cell invasion through the Matrigel after 24 hours’ incubation was detected by H&E staining and quantitated. (D and E) Matrigel invasion assay was performed after resuspending MDA-MB231 cells in the conditioned media collected from pcDNA3.1-Neo–, TβRIII-, and sTβRIII-transfected COS-7 cells. Data are mean ± SEM, n = 3 in triplicate. **P < 0.01. (F) Detection of sTβRIII in media of MDA-MB231–TβRIII and 4T1-TβRIII cells by [¹²⁵I]TGF-β1–binding crosslinking followed by immunoprecipitation.